Library
Tesamorelin
Tesa
FDA-approved for reducing visceral (belly) fat
01 — OVERVIEW
SYSTEMSHow Tesamorelin affects you
Stimulates the pituitary to release GH.
A stabilized analog of growth hormone-releasing hormone (GHRH). Binds pituitary GHRH receptors and triggers natural GH pulses, which lift IGF-1.
GH pulse
+100%
amplitude
IGF-1
+50–80%
- Preserves the pulsatile pattern of endogenous GH release.
- Evening dosing leverages the body's natural GH-release rhythm.
- IGF-1 rises are typically modest and well-tolerated.
Tesamorelin triggers your pituitary gland to release growth hormone, which helps break down visceral fat — the fat stored around your organs. It's one of the few peptides with FDA approval, backed by real clinical trials for this use.
02 — PHARMACOKINETICS
How long it stays, how it leaves.
Half-life
30 min
Default concentration
2000 mcg
Common vial sizes
2000 mcg
Fixed dosing — not weight-adjusted. The calculator handles reconstitution math for common vial sizes so you inject the right volume every time.
03 — DOSING PROTOCOL
Three tiers, three goals.
beginner12 weeks cycle
Dose
1–1 mg
Frequency
Once daily
Cycle
12 weeks
intermediate12-26 weeks cycle
Dose
1–2 mg
Frequency
Once daily
Cycle
12-26 weeks
advanced26 weeks cycle
Dose
2–2 mg
Frequency
Once daily
Cycle
26 weeks
FDA-approved dose is 2mg/day
04 — SIDE EFFECTS
What people actually report.
- Redness at injection spot
- Joint pain
- Swelling in hands/feet
- Tingling/numbness
05 — WARNINGS
Before you start.
- FDA-approved — one of the most studied peptides
- Has real clinical trial data behind it
- Don't use if you have active cancer
06 — STACKING & INTERACTIONS
Combinations worth knowing.
Fat Loss Stack
Tesamorelin burns belly fat through growth hormone while AOD-9604 burns fat directly. Attacks fat from two different angles.
07 — CITATIONS & Q&A
Research behind the claims.
Tesamorelin reduced visceral adipose tissue by ~15% and improved lipid profiles in HIV-positive patients with lipodystrophy.
Comprehensive review confirming tesamorelin's FDA-approved efficacy and tolerability for visceral fat accumulation in HIV patients.